CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 9, 2019
Result type: Reports
Project Number: SR0575-000
Product Line: Reimbursement Review

Generic Name: tofacitinib

Brand Name: Xeljanz

Manufacturer: Pfizer Canada Inc.

Indications: Arthritis, Psoriatic

Manufacturer Requested Reimbursement Criteria1:

For the treatment of adult patients with active psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Submission Type: Initial

Project Status: Cancelled

Anticipated Date: July 11, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.